PPARG and inflammatory bowel disease: While this hypothesis requires experimental validation, it highlights the unique capacity of miR-223 to concurrently inhibit pro-inflammatory (FOXO1/M1) and activate anti-inflammatory (PPAR-γ/M2) pathways, offering a dual-pronged strategy to rebalance macrophage dynamics in IBD.